Abstract |
A sensitive method for the determination of an anti- cancer agent, DX-52-1 (7-cyanoquinocarcinol, I) and quinocarmycin (II) which is formed from I either by metabolism or degradation, in human plasma has been developed utilising liquid chromatography electrospray-ionization tandem mass spectrometry (LC-ESI-MS-MS). The procedure involves solid-phase extraction at pH 2 and low temperature (4-6 degrees C) to prevent the decomposition of I to II, the separation by reversed-phase HPLC and the multiple reaction monitoring (MRM) by ESI-MS-MS. The mean precision and accuracy at the lower limit of quantitation (LLOQ) of I, 0.25 ng ml(-1), were 8.7% and - 10.8%, respectively. Since an interfering peak eluting slightly earlier than II was observed on the HPLC of blank plasma, the LLOQ of II was set at 5 ng ml(-1) where the mean precision and accuracy were 15.6% and -9.8%. The results suggested that the method is useful for the simultaneous monitoring of I and II in the clinical trials of I.
|
Authors | K Yamaguchi, E Fuse, M Takashima, T Yasuzawa, T Kuwabara, S Kobayashi |
Journal | Journal of chromatography. B, Biomedical sciences and applications
(J Chromatogr B Biomed Sci Appl)
Vol. 713
Issue 2
Pg. 447-51
(Aug 25 1998)
ISSN: 1387-2273 [Print] Netherlands |
PMID | 9746263
(Publication Type: Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Isoquinolines
- DX 52-1
- quinocarcin
|
Topics |
- Antibiotics, Antineoplastic
(blood)
- Chromatography, Liquid
- Humans
- Isoquinolines
(blood)
- Male
- Mass Spectrometry
- Sensitivity and Specificity
|